Cannonau Past Earnings Performance
Past criteria checks 2/6
Cannonau has been growing earnings at an average annual rate of 46.7%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been declining at an average rate of 97% per year.
Key information
46.7%
Earnings growth rate
116.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -97.0% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Cannonau makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | 0 | 0 | 0 |
| 31 Dec 23 | 0 | 0 | 0 | 0 |
| 30 Sep 23 | 0 | 0 | 0 | 0 |
| 30 Jun 23 | 0 | 0 | 0 | 0 |
| 31 Mar 23 | 0 | 0 | 0 | 0 |
| 31 Dec 22 | 0 | 0 | 0 | 0 |
| 30 Sep 22 | 0 | 0 | 0 | 0 |
| 30 Jun 22 | 0 | 0 | 0 | 0 |
| 31 Mar 22 | 0 | 0 | 0 | 0 |
| 31 Dec 21 | 0 | 0 | 0 | 0 |
| 30 Sep 21 | 0 | 0 | 0 | 0 |
| 30 Jun 21 | 0 | 0 | 0 | 0 |
| 31 Mar 21 | 0 | 0 | 0 | 0 |
| 31 Dec 20 | 0 | 0 | 0 | 0 |
| 30 Sep 20 | 0 | 0 | 0 | 0 |
| 30 Jun 20 | 0 | 0 | 0 | 0 |
| 31 Mar 20 | 0 | 0 | 0 | 0 |
Quality Earnings: CNNC has a large one-off gain of $363.6K impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: CNNC became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CNNC has become profitable over the past 5 years, growing earnings by 46.7% per year.
Accelerating Growth: CNNC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CNNC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: CNNC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.